Johnson & Johnson-partnered Medivir is pushing ahead with previously mooted plans to cleave its business in two.

Clovis Oncology will look to pay out a higher level of milestone payments, but at a later date, to Pfizer for its licensed PARP inhibitor, as it looks to shore…

Ariad Pharmaceuticals has finished sending its latest data for brigatinib to the FDA and is now looking to the U.S. regulator for a speedy review.

California biotech Rigel Pharmaceuticals has posted positive new late-stage data for its experimental thrombocytopenia treatment and says it is eyeing a 2017…

Weak Phase III data have dealt a blow to Vectura’s hopes of seeing Flutiform approved for use in chronic obstructive pulmonary disease patients.

Immuno-oncology antibody company Leap Therapeutics has reverse merged with Israeli public wound care player Macrocure.

The Asian unit of perpetual life science backer OrbiMed has led a modest $9.7 million first round for biotech CBT Pharmaceuticals as it looks to build up its c…

Fresh off the $1.25 billion Flexus sale, Terry Rosen is aiming to build a major immuno-oncology biopharma from the ground up with upstart Arcus Biosciences.